Skip to main content
OpenTrials
Completed

NCT Number: NCT06118866

A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Androgenetic Alopecia Alopecia Hair Diseases Hypotrichosis Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–65 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Peking University People's Hospital

Beijing, Beijing Municipality, 100035, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
  • Male subjects, between 18 and 65 years of age, inclusive, at the time of signing informed consent.
  • Clinical diagnosis of androgenetic alopecia. Male subjects who meet Norwood-Hamilton scales III vertex, IV and V .
  • Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions, including having a small circle about 1 cm2 of hair clipped to approximate 1 mm in length and micro-dot-tattoo on the scalp of target area.
  • Subjects who are willing to keep the same hair color, refrain from hair weaving, and hair growth therapy and supplement (except for protocol specified IMP) during the study.
  • Subjects agree to use required birth control methods from signing the consent until 3 months after the last dose of IMP or complete whole study period whichever is longer.

Exclusion criteria

  • Subject with history of scalp radiation or surgery which could interfere study assessment (e.g., hair transplantation surgery).
  • Subject with history of scalp laser treatment within 6 months prior screening, including but not limited to, low level laser, and fractional laser, etc.
  • Subject with history of hair weaves within 3 months prior screening.
  • Subject has a current history of hyperthyroidism or uncontrolled hypothyroidism.
  • Subject has, in the Investigator's opinion, uncontrolled hypertension (systolic blood pressure [SBP] > 159 mmHg, diastolic blood pressure [DBP] > 99 mmHg).
  • Subject has any of the following conditions within 6 weeks prior to Screening:
  • Myocardial infarction, stroke, unstable angina, or transient ischemic attack.
  • Heart failure with classified as being in New York Heart Association Class III or IV.
  • Subject has high fever, major surgery, or ten percent or more weight decrease within three months before screening.
  • Subject with history of active malignancy (with or without systemic chemotherapy), except treated basal cell carcinoma of the skin (besides scalp).
  • Subject plans to schedule elective surgery during the study.

Treatment and study plan

placebo-Q2W

Drug

placebo, 0mg，SC，Q2W，12 cycles

HMI-115-120mg-Q4W

Drug

HMI-115, 120mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)

HMI-115-240mg-Q4W

Drug

HMI-115, 240mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)

HMI-115, 240mg-Q2W

Drug

HMI-115, 240mg，SC，Q2W，12 cycles

Primary outcomes

  1. The Rate of Target Arean Hair Count (TAHC)

    Time frame: 24 Weeks

    The mean change in TAHC of non-vellus from baseline

Secondary outcomes

  1. Hair Growth State Assessed by Hair Growth Questionnaire Assessment (HGQA)

    Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks

    To assess the hair growth by 7-question questionnaire and summary the number and percentage of subjects in each category for each HGQA question.

  2. Target Area Hair Count (TAHC) change from baseline

    Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks

    The mean change in TAHC of non-vellus from Baseline

  3. Rate of Target Area Hair Width (TAHW)

    Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks

    The mean change in TAHW of non-vellus from baseline

  4. Investigator Global Assessment (IGA)

    Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks

    Summary of subject number and percentage in each IGA category

  5. Subject Self-Assessment (SSA)

    Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks

    Summary of subject number and percentage in each SSA category

  6. Norwood-Hamilton Grade change from baseline

    Time frame: 12 weeks, 24 weeks, and 36 weeks

    Summary of subject number and percentage in each grade of Norwood-Hamilton Scale

  7. Frequencies and percentages of Adverse event (AE)

    Time frame: 36Weeks

    Frequency and percentages of subjects with treatment-emergent AE (TEAE) will be calculated and TEAE will be summarized by systematic organ classification (SOC), preferred term (PT), relationship to study treatment, maximum severity, whether resulting in death, whether resulting in study treatment discontinuation, belong to serious AE (SAE) or not, belong to events of special interest (AESI) or not.

  8. Blood Pressure change from baseline

    Time frame: 36 Weeks

    Descriptive statistics summarizing changes in blood pressure (systolic and diastolic) will be compared between baseline levels and each predetermined time point.

  9. Pulse change from baseline

    Time frame: 36 Weeks

    Descriptive statistics summarizing changes in pulse will be compared between baseline levels and each predetermined time point.

  10. Body temperature change from baseline

    Time frame: 36 Weeks

    Descriptive statistics summarizing changes in body temperature will be compared between baseline levels and each predetermined time point.

  11. Respiratory rate

    Time frame: 36 Weeks

    Descriptive statistics summarizing changes in respiratory rate will be compared between baseline levels and each predetermined time point.

  12. Complete or brief physical examination, at a minimum of General appearance, HEENT (head, eyes, ears, nose, throat), Neck, Lung/pulmonary, Chest, Neurological or not, Extremities,ect.to assess the physical health state.

    Time frame: 36 Weeks

    Physical examination findings by body system will be summarized, presented with frequency counts and percentages. A complete or brief physical examination will be performed at Visit 1, Visit 2, End of Treatment Visit and Follow-up Visit. Height (cm) and weight (kg) will be measured and body mass index will be calculated and recorded at specified period.

  13. Concomitant Medication

    Time frame: 36 Weeks

    Concomitant medication usage will be summarized by the number and proportion of subjects and classified by the World Health Organization Drug Dictionary (WHO DD) based on Anatomical Therapeutic Chemical Classification System (ATC) code level 3.

  14. Change in twelve-lead electrocardiogram parameters

    Time frame: 36 Weeks

    Change in electrocardiogram parameters including heart rate (HR), QRS, RR, PR, and QT interval (QTcF and QTcB) relative to baseline will be summarized descriptively by visits and groups. The within-group changes from baseline to each visit will be summarized and will be compared with a paired t-test for continuous measurements. Subject number and percentage with other clinically significant electrocardiogram findings in each visit will be summarized by groups. A general assessment of the 12-lead electrocardiogram will be presented as normal, abnormal clinical significance, or abnormal no clinical significance.

  15. Clinical laboratory tests of hematology

    Time frame: 36 Weeks

    Descriptive statistics summarizing changes in results of clinical laboratory tests of hematology from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.

  16. Clinical laboratory tests of coagulation

    Time frame: 36 Weeks

    Descriptive statistics summarizing changes in results of clinical laboratory tests of coagulation from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.

  17. Clinical laboratory tests of clinical chemistry

    Time frame: 36 Weeks

    Descriptive statistics summarizing changes in results of clinical laboratory tests of clinical chemistry from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.

  18. Clinical laboratory tests of urinalysis

    Time frame: 36 Weeks

    Descriptive statistics summarizing changes in results of clinical laboratory tests of urinalysis from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.

  19. Clinical laboratory tests of hormones

    Time frame: 36 Weeks

    Descriptive statistics summarizing changes in results of clinical laboratory tests of hormones from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.

Sponsors and collaborators

Lead sponsor

Hope Medicine (Nanjing) Co., Ltd

Industry

Registry information

Official study title

A Randomized, Multicenter, Double-blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy in Male Androgenetic Alopecia Treated With HMI-115 Over a 24-Week Treatment Period

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Nov 7, 2023
Registry last updated
Jun 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.